Retension Pharmaceuticals, Inc. has set the price of its initial public offering at $12 per share, according to wire reports reviewed by FXMARE. The offering was upsized from its original plan, and coverage of the announcement describes proceeds of roughly $45 million.
The company trades under the ticker RTSN, and the reporting indicates the shares are being listed on Nasdaq. One report describes the deal as an offering of 3.75 million shares, though the snippet available to FXMARE is cut off at that point, so further details of the share count and structure are not confirmed here.
Retension is described as a clinical-stage biopharmaceutical company. Its stated focus is the development of treatments for cardiovascular diseases. A clinical-stage designation generally means a company's drug candidates are still being tested in human trials and have not yet received regulatory approval for sale, although the source material does not specify which programs Retension is advancing or at what phase.
The decision to upsize the offering is a notable feature of the announcement. An enlarged deal typically signals that the company chose to sell more shares than first planned, but the supplied reports do not explain the reasoning behind the change, give the original terms, or say how the pricing compares with any earlier indicated range. FXMARE has therefore not attempted to characterize investor demand.
The available coverage also does not detail how the company intends to use the proceeds, name the underwriters, or state when trading is expected to begin or when the offering is due to close. Those items are customarily covered in the formal offering documents and company statements, which were not part of the material reviewed.
For the broader equity market, the pricing adds a new clinical-stage healthcare name to the roster of Nasdaq-listed companies. Further information on first-day trading and on the company's pipeline will be needed to put the debut in fuller context.